Latest Health News

Bathurst Resources reported a Q1 FY26 EBITDA of NZD 5.2 million, maintaining full-year guidance and progressing major development projects in New Zealand and Canada.

Pro-Pac Packaging has entered voluntary administration, securing relief to defer its financial reporting and annual general meeting obligations for up to two years. This move pauses key corporate governance duties as the company navigates its restructuring.

Atomos Limited has posted its first positive EBITDA quarter since late 2022, driven by strong sales of its flagship Ninja and Shinobi products. The company’s operational overhaul and strategic product launches set the stage for continued growth into Q2 FY26.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.

Winsome Resources has completed a focused drilling campaign at its Adina Lithium Project and revealed new high-grade cesium-lithium mineralised zones at Sirmac-Clapier, while strengthening its stake in Power Metals Corp.

Liontown Resources delivered a robust September quarter with a significant ramp-up in underground mining at Kathleen Valley, alongside a fortified cash position and strategic contract amendments.

Global Health Limited has accelerated its MasterCare+ SaaS platform rollout, integrating AI to streamline operations and reduce staff by 10%, while reporting a 25% EBIT improvement despite a delayed R&D refund impacting cash flow.

CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.

XPON Technologies reports a robust Q1 FY26 with 17.5% revenue growth, positive cash flow, and strategic leadership changes, setting a strong foundation for the year ahead.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.